Pharmafile Logo
Pharmafocus logo
Advanced Search

Shire thrives on specialist portfolio

February 11, 2011
Sales and Marketing 2010 pharma results, ADHD, Shire, Vyvanse

Speciality pharma company Shire has posted sales growth of 16%, led by its ADHD treatment Vyvanse. Sales of Vyvanse rose …

News

Pierre Fabre loses chief executive

February 11, 2011
Sales and Marketing Olivier Bohuon, Pierre Fabre, Smith & Nephew, appointment, medical devices, sales and marketing

Olivier Bohuon is leaving French pharma company Pierre Fabre after serving just five months as its chief executive. He will …

Appointment
ABPI Code of Practice

Cephalon in trouble over party spirit

February 11, 2011
Medical Communications ABPI, ABPI Code of Practice, Cephalon, PMCPA, industry reputation

Cephalon has been criticised by UK authorities for bankrolling “excessive” hospitality at a conference in Lisbon.The company was cited by …

News

TBWA Paling Walters adds to management board

February 11, 2011
Medical Communications Andy Hayley, Ed Shorthose, Steve Morris, TBWA/Paling Walters, appointment, medical communications

London-based advertising agency TBWA\ Paling Walters has promoted Steve Morris and Ed Shorthose to the roles of managing partners. They …

News
Eli Lilly chief executive John Lechleiter

Lilly chief issues warning on UK reforms

February 11, 2011
Research and Development, Sales and Marketing John Lechleiter, US health reforms, healthcare reform, lilly, patent box, value-based pricing

Lilly chief executive John Lechleiter has warned that two key UK initiatives could fall seriously short of encouraging investment in …

News

Innovation is being stifled – Lilly chief executive

February 10, 2011
Research and Development, Sales and Marketing Economist 2011 Pharma Summit, US health reforms, healthcare costs, healthcare reform, lilly

Supporting medical innovation should be a fundamental requirement of healthcare reforms, but current public policies are failing to do this, …

News
Blog footer

Digital Pharma: This is how pharma is using digital

February 10, 2011
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Android, Digital Pharma blog, Facebook, Twitter, disease awareness campaigns, ipad, iphone, social media

Pharma’s use of digital tools, from mobile apps to online campaigns to social media channels, is increasing all the time …

Feature

Amarin expands US operations

February 10, 2011
Sales and Marketing AMR101, Amarin, Paul Huff, high cholesterol

Dublin-based biopharmaceutical company Amarin is to increase its US presence by setting up sales and marketing headquarters in New Jersey. …

News
GSK's swine flu vaccine Pandemrix

WHO wants narcolepsy link with swine flu vaccine investigated

February 10, 2011
Research and Development, Sales and Marketing Finland Institute, GSK, GlaxoSmithKline, Pandemrix, narcolepsy, swine flu

The World Health Organisation has called for further investigation into GSK’s swine flu vaccine link to sleeping disorder narcolepsy, following …

News

Dr Mikael von Euler moves to Oncos Therapeutics

February 10, 2011
Research and Development Dr Mikael von Euler, Oncos Therapeutics, appointment, research and development

Finnish biotech company Oncos Therapeutics has appointed Dr Mikael von Euler as chief medical officer. He has more than 20 …

Appointment

Alliance concerned over NHS competition reforms

February 10, 2011
Health and Social Care Bill, NHS, NHS Alliance, NHS reforms

The NHS Alliance has called on the Government to clarify major issues around the Health and Social Care Bill which …

News

Generics force Sanofi into standstill

February 9, 2011
Sales and Marketing 2010 pharma results, Jevtana, Multaq, Sanofi, Sanofi-Aventis, generics

An onslaught of generic competition combined with healthcare cuts in the US and Europe meant Sanofi-Aventis’ revenues were brought to …

News

Shire bags senior research execs from GSK and Abbott

February 9, 2011
Research and Development Dr Lawson Macartney, Dr Mario Saltarelli, Shire, appointment, recruitment, research and development

Shire has strengthened its speciality pharmaceuticals business with the appointment of senior research executives from GlaxoSmithKline and Abbott. Dr Lawson …

News
Diabetes injection

Pharma-NHS diabetes project begins

February 9, 2011
Sales and Marketing AstraZeneca, Lilly UK, MSD, NHS, Nottingham, Novartis, Novo Nordisk, Pfizer, Sanofi-Aventis, joint working

A joint venture between the NHS, charities and the pharma sector has begun in Nottingham to help treat the city’s …

News

Teva surges ahead

February 9, 2011
Sales and Marketing 2010 pharma results, Copaxone, Teva, Teva Pharmaceutical

Generics giant Teva enjoyed a strong year of growth in 2010, lifted by the acquisition of Ratiopharm, patent expiries of …

News

Dr Matthias joins Noxxon Pharma

February 9, 2011
Research and Development Dr Matthias Baumann, Noxxon Pharma, appointment, research and development

Berlin-based biotech Noxxon Pharma has appointed Dr Matthias Baumann as chief medical officers. He joins from Focus Clinical Drug Development, …

Appointment
Advanced melanoma

Melanoma: intense competition to be the next milestone treatment

February 9, 2011
Research and Development BRAF V600 mutation, Cancer, Tasigna, cancer research, melanoma, tremelimumab

A flurry of new data has emerged in the recent months from an industry-wide pipeline of cancer drugs which could …

Feature

AZ-Targacept depression candidate moves into phase IIb

February 9, 2011
Research and Development AZ, AstraZeneca, TC-5214, Targacept, depression, major depressive disorder

AstraZeneca and Targacept have begun a phase IIb trial of TC-5214 as a ‘switch’ monotherapy for patients with depression. The …

News

Early diagnosis key to UK cancer ambition

February 8, 2011
Cancer, NHS, NICE

A series of quality standards on cancer care is to be drawn up by NICE as part of a new …

Feature

Genzyme to divest pharma intermediates business

February 8, 2011
Manufacturing and Production Cerezyme, Corden Pharma Switzerland, Corden Pharma group, Genzyme, International Chemical Investors Group, Sekisui Chemical Co, imiglucerase

Genzyme has agreed to sell off its pharmaceutical intermediates business to International Chemical Investors Group, a holding company which has …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026